Management Change19 Jun 2026, 05:00 pm
Albert David Appoints Amit Mahla as Whole-time Director & CEO
AI Summary
Albert David Ltd announced the appointment of Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO, effective June 19, 2026. This appointment, along with his remuneration, is subject to shareholder approval at the upcoming 87th Annual General Meeting (AGM). Mr. Mahla, who has over 28 years of experience in the pharmaceutical industry and previously served as CEO since May 12, 2026, will hold the position of Whole-time Director & CEO for a term of 5 years until June 18, 2031. The company also revised the notice for its 87th AGM to include these resolutions.
Key Highlights
- Amit Mahla appointed Additional Director and Whole-time Director & CEO.
- Appointment is for a 5-year term, subject to shareholder approval.
- Mr. Mahla brings over 28 years of pharmaceutical industry experience.
- Remuneration fixed for the period June 19, 2026, to March 31, 2027.
- Revised AGM notice to include resolutions for Mr. Mahla's appointment.
Price Impact
More from ALBERTDA